Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?

Paulo    Gustavo    Kotze; Silvio       Danese

« Previous Next »

[1] 
Ribeiro, P.; Fiorino, G.; Danese, S. The Experience with biosimilars of infliximab in inflammatory bowel disease. Curr. Pharm. Des.,  2017, 23(44), 6759-6769.
[2] 
Michetti, P. Efficacy of infliximab biosimilars in patients with Crohn’s disease. Lancet,  2017, 390(10111), 2435.
[3] 
Martelli, L.; Peyrin-Biroulet, L. Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: A systematic review. Curr. Med. Chem.,  2019, 26(2), 270-279.
[4] 
Magro, F.; Coelho, R.; Peixoto, A. Can we extrapolate data from one immune-mediated inflammatory disease to another one? Curr. Med. Chem.,  2019, 26(2), 248-258.
[5] 
Gulacsi, L.; Pentek, M.; Rencz, F.; Brodszky, V.; Baji, P.; Vegh, Z.; Gecse, K.B.; Danese, S.; Peyrin-Biroulet, L.; Lakatos, P.L. Biosimilars for the management of inflammatory bowel diseases: Economic considerations. Curr. Med. Chem.,  2019, 26(2), 259-269.
[6] 
Danese, S.; Fiorino, G. Anti-TNF biosimilars in inflammatory bowel disease: Searching the proper patient’s profile. Curr. Med. Chem.,  2019, 26(2), 280-287.

Download Options